Stay updated on Blinatumomab & Pembrolizumab in B-ALL Clinical Trial
Sign up to get notified when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.

Latest updates to the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page
- Check5 days agoChange DetectedThe clinical trial record for blinatumomab plus pembrolizumab in adults with relapsed or refractory B-cell ALL is displayed, with study details, outcome measures, eligibility criteria, locations, and supporting documents.SummaryDifference58%

- Check12 days agoChange DetectedThe page remains a 403 Forbidden error page instead of showing the clinical study record. The footer’s site revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAn NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears on the error page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check54 days agoChange DetectedAccess to the study page is blocked by a 403 Forbidden error, replacing the trial content with a minimal error screen and a Home link.SummaryDifference19%

- Check61 days agoChange DetectedThe page was updated to revision 3.7.0, replacing the previous 3.6.6. This reflects a software release without changes to the displayed study content.SummaryDifference0.1%

Stay in the know with updates to Blinatumomab & Pembrolizumab in B-ALL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.